SCHEMBL2456950

SCHEMBL2456950

Cc1nnc(C)c(-c2ccc(Cl)cc2)c1O

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 3/20 0.42
KMT2A Q03164 3/20 0.42
GYS1 P13807 1/20 0.42
IKBKB O14920 1/20 0.41
MAP3K14 Q99558 1/20 0.41
MAPT P10636 6/20 0.39
HTT P42858 3/20 0.39
GAA P10253 2/20 0.39
MAPK1 P28482 2/20 0.39
NPSR1 Q6W5P4 2/20 0.39
CYP1A2 P05177 1/20 0.39
CYP3A4 P08684 1/20 0.39
CYP2D6 P10635 1/20 0.39
CYP2C9 P11712 1/20 0.39
ALOX15 P16050 1/20 0.39
ALOX12 P18054 1/20 0.39
CYP2C19 P33261 1/20 0.39
GPR55 Q9Y2T6 1/20 0.39
SENP1 Q9P0U3 1/20 0.38
ALDH1A1 P00352 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2455752 0.79 MEN1 (0.44) MEN1KMT2AIKBKBMAP3K14MAPT
SCHEMBL2453925 0.76 MEN1 (0.42) MEN1KMT2AIKBKBMAP3K14MAPT
SCHEMBL3054900 0.75 SENP1 (0.50) MEN1KMT2AGYS1IKBKBMAP3K14
SCHEMBL13754692 0.73 KMT2A (0.39) MEN1KMT2AGYS1IKBKBMAP3K14
SCHEMBL3577494 0.72 ALOX5 (0.43) MEN1KMT2AGYS1IKBKBMAP3K14
SCHEMBL2848598 0.71 ESR1 (0.37) MEN1KMT2AIKBKBMAP3K14MAPT
SCHEMBL13069099 0.71 NPC1 (0.50) MEN1KMT2AALDH1A1KDM4ELMNA
SCHEMBL68893 0.71 NPC1 (0.47) MEN1KMT2AIKBKBMAP3K14MAPT
SCHEMBL12198449 0.70 MAPT (0.43) MEN1KMT2AMAPTHTTGAA
SCHEMBL3971627 0.69 RAB9A (0.39) MEN1KMT2AIKBKBMAP3K14MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1958948-B1 PYRIDAZINE COMPOUND AND USE THEREOF SUMITOMO CHEMICAL CO (JP) 2011-10-05 EP disclosed
EP-1958948-B1 PYRIDAZINE COMPOUND AND USE THEREOF SUMITOMO CHEMICAL CO (JP) 2011-10-05 EP disclosed
US-8022073-B2 Substituted pyridazine compounds and fungicidal uses thereof SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2011-09-20 US disclosed
US-8022073-B2 Substituted pyridazine compounds and fungicidal uses thereof SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2011-09-20 US disclosed
US-20090156608-A1 Pyridazine Compound and Use Thereof SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2009-06-18 US disclosed
US-20090156608-A1 Pyridazine Compound and Use Thereof SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2009-06-18 US disclosed
EP-1958948-A1 PYRIDAZINE COMPOUND AND USE THEREOF Sumitomo Chemical Company, Limited (JP) 2008-08-20 EP disclosed
EP-1958948-A1 PYRIDAZINE COMPOUND AND USE THEREOF Sumitomo Chemical Company, Limited (JP) 2008-08-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090156608-A1 Pyridazine Compound and Use Thereof PLPBP, PNPO, PDXK MEN1 3015/4885KMT2A 1894/4885GYS1 2971/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.